IMM60

IMM60 is a synthetically derived small molecule agonist of invariant natural killer T (iNKT) cells, formulated in a liposomal delivery system (also referred to as PORT-2). It is designed to optimally activate both the innate and adaptive immune responses by engaging iNKT cells, which can directly kill CD1d-expressing tumor cells and induce long-lasting antitumor CD8+ T cell responses through dendritic cell cross priming. Preclinical studies show that IMM60 matures dendritic and B cells, stimulates IFN-gamma production from iNKT cells, upregulates PD-L1 on cancer cells, and can overcome resistance to PD-1 antibody therapy. Clinically, it is being investigated as monotherapy or in combination with pembrolizumab for advanced melanoma and non-small cell lung cancer (NSCLC), with early trials indicating favorable safety when administered intravenously[1][5][8][9].

Other names

IMM60IMM-60IMM 60PORT-2PORT2PORT 2